BR0314006A - Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêutica - Google Patents
Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêuticaInfo
- Publication number
- BR0314006A BR0314006A BR0314006-7A BR0314006A BR0314006A BR 0314006 A BR0314006 A BR 0314006A BR 0314006 A BR0314006 A BR 0314006A BR 0314006 A BR0314006 A BR 0314006A
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- disease
- group
- disease selected
- lupus
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 208000037147 Hypercalcaemia Diseases 0.000 title abstract 3
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 230000000148 hypercalcaemia Effects 0.000 title abstract 3
- 208000030915 hypercalcemia disease Diseases 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 2
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 210000000056 organ Anatomy 0.000 title abstract 2
- 231100000816 toxic dose Toxicity 0.000 title abstract 2
- 229930003231 vitamin Natural products 0.000 title abstract 2
- 229940088594 vitamin Drugs 0.000 title abstract 2
- 235000013343 vitamin Nutrition 0.000 title abstract 2
- 239000011782 vitamin Substances 0.000 title abstract 2
- -1 vitamin compound Chemical class 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 206010052779 Transplant rejections Diseases 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 7
- 210000000988 bone and bone Anatomy 0.000 abstract 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 4
- 229910052791 calcium Inorganic materials 0.000 abstract 4
- 239000011575 calcium Substances 0.000 abstract 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 abstract 2
- 229930003316 Vitamin D Natural products 0.000 abstract 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 2
- 230000002308 calcification Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 235000019166 vitamin D Nutrition 0.000 abstract 2
- 239000011710 vitamin D Substances 0.000 abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
- 229940046008 vitamin d Drugs 0.000 abstract 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 229940062527 alendronate Drugs 0.000 abstract 1
- 210000000709 aorta Anatomy 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/235,244 US7259143B2 (en) | 2002-09-05 | 2002-09-05 | Method of extending the dose range of vitamin D compounds |
| PCT/US2003/020517 WO2004022068A1 (en) | 2002-09-05 | 2003-06-26 | A method of extending the dose range of vitamin d compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0314006A true BR0314006A (pt) | 2005-08-09 |
Family
ID=31977538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314006-7A BR0314006A (pt) | 2002-09-05 | 2003-06-26 | Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7259143B2 (enExample) |
| EP (1) | EP1545549A1 (enExample) |
| JP (1) | JP2006500388A (enExample) |
| KR (1) | KR100835456B1 (enExample) |
| CN (1) | CN1694711A (enExample) |
| AU (2) | AU2003245748A1 (enExample) |
| BR (1) | BR0314006A (enExample) |
| CA (1) | CA2497828A1 (enExample) |
| MX (1) | MXPA05002467A (enExample) |
| NZ (1) | NZ539129A (enExample) |
| PL (1) | PL375558A1 (enExample) |
| WO (1) | WO2004022068A1 (enExample) |
| ZA (1) | ZA200501843B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| WO2003086415A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US7566696B2 (en) * | 2002-09-05 | 2009-07-28 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| NZ545862A (en) * | 2003-08-20 | 2010-01-29 | Wisconsin Alumni Res Found | 2-Methylene-19-nor-vitamin D2 compounds |
| CA2539361A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| WO2005027929A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen |
| US7704980B2 (en) * | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
| WO2006061683A1 (en) * | 2004-12-09 | 2006-06-15 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta |
| US20060195353A1 (en) * | 2005-02-10 | 2006-08-31 | David Goldberg | Lead generation method and system |
| CA2597624C (en) * | 2005-02-11 | 2012-08-14 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2 |
| US7511030B2 (en) * | 2005-02-11 | 2009-03-31 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2 |
| JP2008530121A (ja) * | 2005-02-14 | 2008-08-07 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | 多発性硬化症を治療および予防するためのカルシトニンおよびカルシトニン様ペプチド類の使用 |
| WO2007022433A2 (en) * | 2005-08-18 | 2007-02-22 | Bioxell S.P.A. | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL |
| US20070165866A1 (en) * | 2006-01-13 | 2007-07-19 | Motorola, Inc. | Method and apparatus to facilitate conveying audio content |
| PT2148661E (pt) * | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| US20100331286A1 (en) * | 2008-02-25 | 2010-12-30 | Ray Chow | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function |
| TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
| TR200900880A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik bileşimler. |
| AU2010300539B9 (en) * | 2009-10-02 | 2018-07-19 | Wisconsin Alumni Research Foundation | 1-desoxy-2-methylene-19-nor-vitamin D analogs and their uses |
| WO2012075326A2 (en) * | 2010-12-01 | 2012-06-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of inflammatory diseases by targeting the adaptor protein ciks |
| WO2013059060A1 (en) * | 2011-10-21 | 2013-04-25 | Wisconson Alumni Research Foundation | 2-methylene-vitamin d analogs and their uses |
| US9688596B2 (en) * | 2015-08-05 | 2017-06-27 | Wisconsin Alumni Research Foundation | Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
| US5391567A (en) * | 1986-09-03 | 1995-02-21 | Macrochem Corporation | Method for treating hypercalcemia using salts of TNCA |
| US6489288B1 (en) * | 1990-03-16 | 2002-12-03 | Applied Research Systems Ars Holding | Treatment of polycystic ovarian disease |
| US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6503893B2 (en) * | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6034075A (en) * | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| EP1267888A4 (en) | 2000-01-04 | 2005-12-28 | Univ California | USE OF LOW DOSE BISPHOSPHONATES TO INHIBIT CARDIAC AND ARTERIAL CALCIFICATION |
| IL159853A0 (en) * | 2001-07-17 | 2004-06-20 | Teva Pharma | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
-
2002
- 2002-09-05 US US10/235,244 patent/US7259143B2/en not_active Expired - Fee Related
-
2003
- 2003-06-26 MX MXPA05002467A patent/MXPA05002467A/es active IP Right Grant
- 2003-06-26 KR KR1020057003765A patent/KR100835456B1/ko not_active Expired - Fee Related
- 2003-06-26 PL PL03375558A patent/PL375558A1/xx not_active Application Discontinuation
- 2003-06-26 CN CNA038248883A patent/CN1694711A/zh active Pending
- 2003-06-26 CA CA002497828A patent/CA2497828A1/en not_active Abandoned
- 2003-06-26 NZ NZ539129A patent/NZ539129A/en not_active IP Right Cessation
- 2003-06-26 AU AU2003245748A patent/AU2003245748A1/en not_active Abandoned
- 2003-06-26 JP JP2004534233A patent/JP2006500388A/ja active Pending
- 2003-06-26 EP EP03739354A patent/EP1545549A1/en not_active Withdrawn
- 2003-06-26 WO PCT/US2003/020517 patent/WO2004022068A1/en not_active Ceased
- 2003-06-26 BR BR0314006-7A patent/BR0314006A/pt not_active IP Right Cessation
-
2005
- 2005-03-03 ZA ZA200501843A patent/ZA200501843B/en unknown
-
2009
- 2009-09-21 AU AU2009217403A patent/AU2009217403A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05002467A (es) | 2005-05-27 |
| CA2497828A1 (en) | 2004-03-18 |
| WO2004022068A1 (en) | 2004-03-18 |
| US20040053813A1 (en) | 2004-03-18 |
| JP2006500388A (ja) | 2006-01-05 |
| AU2003245748A1 (en) | 2004-03-29 |
| KR100835456B1 (ko) | 2008-06-09 |
| ZA200501843B (en) | 2006-05-31 |
| CN1694711A (zh) | 2005-11-09 |
| AU2009217403A1 (en) | 2009-10-08 |
| EP1545549A1 (en) | 2005-06-29 |
| PL375558A1 (en) | 2005-11-28 |
| NZ539129A (en) | 2008-05-30 |
| US7259143B2 (en) | 2007-08-21 |
| KR20050057180A (ko) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0314006A (pt) | Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêutica | |
| DeLuca | The vitamin D story: a collaborative effort of basic science and clinical medicine 1 | |
| CN1250225C (zh) | 2α－甲基－19－去甲－20(S)－1α,25－二羟维生素D3生产用于增加骨强度的药物的用途 | |
| JP4493340B2 (ja) | １α−ヒドロキシ−２−メチレン−１９−ノル−プレグナカルシフェロール及びその使用 | |
| Brown | Vitamin D analogues | |
| US20040033998A1 (en) | (20S)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses | |
| Brown et al. | New active analogues of vitamin D with low calcemic activity. | |
| BR0309405A (pt) | Compostos e métodos de tratamento da psorìase de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer de peito ou câncer de próstata, de doença autoimune, de doença inflamatória, de condição de pele e de doença metabólica do osso | |
| JPH03504508A (ja) | 新規な１α―ヒドロキシビタミンＤ２エピマー、その誘導体及びそれらを含んでなる調剤 | |
| MX2010001987A (es) | Un metodo para extender el intervalo de dosificacion de compuestos de vitamina d. | |
| CN1455672A (zh) | 2－亚甲基－19－去甲－20(S)－1α，25－二羟维生素D3增加骨强度的用途 | |
| Norman | The vitamin D endocrine system: Manipulation of structure‐function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents | |
| ATE537834T1 (de) | 2-methylen-19-nor-vitamin d2-verbindungen | |
| KR100983953B1 (ko) | 신생 골의 형성을 유도하기 위한 탄소-2-개질된 19-노르-비타민 ｄ 유사체의 용도 | |
| Opolski et al. | Biological activity in vitro of side-chain modified analogues of calcitriol | |
| EP1722856A1 (en) | Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases | |
| Dekel et al. | Contrasting effects on bone formation and on fracture healing of cholecalciferol and of 1 α-hydroxycholecalciferol | |
| Milne et al. | Vitamin D handbook: structures, synonyms, and properties | |
| US4428946A (en) | Method of preventing milk fever in dairy cattle | |
| Reeve et al. | Biological activity of 1 α-hydroxyvitamin D2 in the rat | |
| Stamp | Vitamin D metabolism. Recent advances | |
| Jacobsson et al. | Distribution of selenium in mice studied by whole-body autoradiography after injection of Se75-sodium selenite | |
| Kittaka | Creation of potent vitamin D receptor agonists and antagonists with 2α-(ω-hydroxyalkylation) concept to the seco-steroid skeleton | |
| Haddad Jr et al. | Phosphorus deprivation: the metabolism of vitamin D3 and 25-hydroxycholecalciferol in rats | |
| JPH06340528A (ja) | ナフタレン誘導体を有効成分とする骨疾患の予防及び治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI. A61K 31/59, A61P 35/00, A61P 17/00 Ipc: A61K 31/59 (2011.01), A61P 35/00 (2011.01), A61P 1 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |